Lentiviral vectors (LVVs), a robust technology for delivering therapeutic genes into cells, and accurate LVV characterization are crucial to help ensure the safety, efficacy and consistency of cell and gene therapies (CGT) for diseases such as cancer, genetic disorders and rare inherited conditions.

Accurate assessment of viral genome titer and vector copy number (VCN) supports consistent product quality, optimal dosing and provides insights into transgene stability and expression. Additionally, testing for replication-competent lentivirus (RCL), an unintended byproduct of recombination, is a critical regulatory requirement mandated by the FDA and EMA to safeguard patient outcomes and ensure treatment integrity.  

In this webinar, experts from QIAGEN and Niba Labs will present a streamlined dPCR-based workflow for quantifying lentiviral genome titers, VCN, and RCL. This enhanced workflow supports standardized, high-precision quality control (QC) and enables both singleplex and multiplex applications. David Dobnik from Niba Labs will also share his end-user perspective, providing first-hand insights into the lab’s experience using these kits in real-world CGT workflows.

A live Q&A session will follow the discussion, where you can engage directly with our panelists and get your questions answered.